Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Global Glaucoma Therapeutics Market Poised for Growth; Set to Reach US$7.2 Billion by 2030 Glaucoma Therapeutics Market ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma ...

Glenmark Pharmaceuticals Inc, USA on Wednesday said it has launched Travoprost ophthalmic solution used in the treatment of ...

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Gland Pharma receives USFDA approval for Latanoprost Ophthalmic Solution, strengthening its position in the US pharmaceutical ...